Skip to main content
. Author manuscript; available in PMC: 2019 Oct 14.
Published in final edited form as: Vasc Med. 2019 Jul 5;24(5):414–421. doi: 10.1177/1358863X19859072

Figure 2.

Figure 2.

Canakinumab treatment leads to an overall decrease in inflammatory biomarkers. Patients were treated monthly with 150 mg canakinumab or placebo sc. There was a decrease (shown here as ratio to baseline) in hsCRP (A) and IL-6 (B) seen as early as 1 month of treatment that appears durable throughout the treatment period compared to placebo.

*p < 0.05 vs placebo.

hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; sc, subcutaneously.